Search results: (10000)
News Effectiveness of Dietary Intervention in Irritable Bowel Syndrome – Results of a Network Meta-Analysis
A low FODMAP diet is often recommended to alleviate symptoms of irritable bowel syndrome (IBS). Although several randomized studies have been conducted to assess the effectiveness of this diet, a systematic evaluation has yet to be available, and individual studies have used various control interventions. Therefore, an international team of researchers decided to prepare a systematic literature review with a network analysis, recently published in the journal Gut.
News How can inosine pranobex help with viral infections?
Inosine pranobex has long been used for its immunomodulatory and antiviral effects in the prophylaxis and therapy of various viral infections. Below we summarize its mechanism of action, indications, usage, and side effects.
News ESC 2022: What Current Insights Say About the Role of Dabigatran in Stroke Prevention with Atrial Fibrillation and Comorbidities
The risk of atrial fibrillation (AF) increases with age as risk factors accumulate and comorbidities arise. What do current data from randomized clinical trials and registries show about stroke prevention (SP) in the context of concurrent AF and some other chronic diseases? This was the focus of one of the symposia at this year's European Society of Cardiology (ESC) Congress.
News ESC 2022: What Do the Latest Real-World Data Say About the Use of DOACs in Atrial Fibrillation?
Why are real-world data so important? What new insights can they provide about established medications, such as direct oral anticoagulants (DOACs), in the treatment of patients with atrial fibrillation (AF)? What makes the GLORIA-AF registry unique, and what insights have been published from it this year? These topics were also discussed at the ESC 2022 Congress.
News ESC 2022: How to use gliflozins in heart failure? American guidelines now also consider the EMPEROR-Preserved study
One of the important current cardiology topics is the possibility of using gliflozins in patients with chronic heart failure (HF) regardless of the left ventricular ejection fraction (LVEF). The possibilities of introducing these medicines into clinical practice, considering the issue in international guidelines, and the results of empagliflozin in recent studies were covered in a practically oriented symposium as part of the professional program of this year's European Society of Cardiology Congress (ESC 2022).